MURF2

Abstract: The invention provides murF2 polypetides and polynucleotides encoding murF2 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing murF2 polypeptides to screen for antibacterial compounds.

Description: murF2 RELATED APPPLICATIONS This application claims benefit to US Provisional Application Number 60/100.894. filed September 23, 1998 FIELD OF THE INVENTION This invention relates to newly identified polynucleotides and polypeptides, and their production and uses, as well as their vaπants, agonists and antagonists, and their uses In particular, the invention relates to polynucleotides and polypeptides of the mur family, as well as their vanants, herein referred to as "murF2," "murF2 polynucleotιde(s)," and "murF2 polypeptιde(s)" as the case may be BACKGROUND OF THE INVENTION The Streptococci make up a medically important genera of microbes known to cause several types of disease in humans, including, for example, otitis media, conjunctivitis, pneumonia, bacteremia. meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid Since its isolation more than 100 years ago, Streptococcus pneumoniae has been one of the more intensively studied microbes For example, much of our early understanding that DNA is. in fact, the genetic material was predicated on the work of Gnffith and of Avery. Macleod and McCarty using this microbe Despite the vast amount of research with S pneumoniae. many questions concerning the virulence of this microbe remain It is particularly preferred to employ Streptococcal genes and gene products as targets for the development of antibiotics The frequency of Streptococcus pneumoniae infections has πsen dramatically in the past few decades This has been attπbuted to the emergence of multiply antibiotic resistant strains and an increasing population of people with weakened immune systems It is no longer uncommon to isolate Streptococcus pneumoniae strains that are resistant to some or all of the standard antibiotics This phenomenon has created an unmet medical need and demand for new anti-microbial agents, vaccines, drug screening methods, and diagnostic tests for this organism Moreover, the drug discovery process is currently undergoing a fundamental revolution as it embraces "functional genomics," that is. high throughput genome- or gene-based biology This approach is rapidly superseding earlier approaches based on "positional cloning" and other methods Functional genomics relies heavily on the vaπous tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available as well as from other sources. There is a continuing and significant need to identify and characterize further genes and other polynucleotides sequences and their related polypeptides, as targets for drug discovery. Clearly, there exists a need for polynucleotides and polypeptides, such as the murF2 embodiments of the invention, that have a present benefit of, among other things, being useful to screen compounds for antimicrobial activity. Such factors are also useful to determine their role in pathogenesis of infection, dysfunction and disease. There is also a need for identification and characterization of such factors and their antagonists and agonists to find ways to prevent, ameliorate or coπect such infection, dysfunction and disease. SUMMARY OF THE INVENTION The present invention relates to murF2, in particular murF2 polypeptides and murF2 polynucleotides, recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including treatment of microbial diseases, amongst others. In a further aspect, the invention relates to methods for identifying agonists and antagonists using the materials provided by the invention, and for treating microbial infections and conditions associated with such infections with the identified agonist or antagonist compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with microbial infections and conditions associated with such infections, such as assays for detecting murF2 expression or activity. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following descriptions and from reading the other parts of the present disclosure. DESCRIPTION OF THE INVENTION The invention relates to murF2 polypeptides and polynucleotides as described in greater detail below. In particular, the invention relates to polypeptides and polynucleotides of a murF2 of Streptococcus pneumoniae, that is related by amino acid sequence homology to gi|1653484|gnl|PID|dl019130 (D90914) hypothetical protein [Synechocystis sp polypeptide. The invention relates especially to murF2 having a nucleotide and amino acid sequences set out in Table 1 as SEQ ID NO:l and SEQ ID NO:2 respectively. Note that sequences recited in the Sequence Listing below as "DNA" represent an exemplification of the invention, since those of ordinary skill will recognize that such sequences can be usefully employed in polynucleotides in general, including ribopolynucleotides. TABLE 1 murF2 Polynucleotide and Polypeptide Sequences (A) Streptococcus pneumoniae murF2 polynucleotide sequence [SEQ ID NO: 1]. 5 ' - ATGAACTTAAAAACTACTTTGGGCCTTCTTGCTGGGCGTTCTTCCCACTTCGTTTTAAGCCGTCTTGGACGTGGA AGTAC GCTCCCAGGGAAAGTCGCCCTTCAATTTGATAAAGATATTTTACAAAACCTAGCTAAGAACTACGAGATTGTCGT TGTCA CTGGAACAAATGGAAAAACCCTGACAACTGCCCTCACTGTCGGCATTTTAAAAGAGGTTTATGGTCAAGTTCTAA CCAAC CCAAGCGGTGCCAACATGATTACAGGGATTGCAACAACCTTCCTAACAGCCAAATCTTCTAAAACTGGGAAAAAT ATTGC CGTCCTCGAAATTGACGAAGCCAGTCTATCTCGTATCTGTGACTATATCCAGCCTAGTCTTTTTGTCATTACTAA TATCT TCCGTGACCAGATGGACCGTTTCGGTGAAATCTATACTACCTATAACATGATATTGGATGCCATTCGGAAAGTTC CAACT GCTACTGTTCTCCTTAACGGAGACAGTCCACTTTTCTACAAGCCAACTATTCCAAACCCTATAGAGTATTTTGGT TTTGA CTTGGAAAAAGGACCAGCCCAACTGGCTCACTACAATACCGAAGGGATTCTCTGTCCTGACTGCCAAGGCATCCT CAAAT ATGAGCATAATACCTATGCAAACTTGGGTGCCTATATCTGTGAGGGTTGTGGATGTAAACGTCCTGATCTCGACT ATCGT TTGACAAAACTGGTTGAGTTGACCAACAATCGCTCTCGCTTTGTCATAGACGGCCAAGAATACGGTATCCAAATC GGCGG GCTCTATAATATCTATAACGCCCTAGCTGCTGTGGCCATCGCCCGTTTCCTAGGTGCCGATTCGCAACTCATCAA ACAGG GATTTGACAAGAGCCGTGCTGTCTTTGGACGCCAAGAAACCTTTCATATCGGTGACAAGGAATGTACCCTTGTCT TGATT AAAAATCCAGTCGGTGCAACCCAAGCTATCGAAATGATCAAACTAGCACCTTATCCATTTAGCCTATCTGTCCTC CTTAA TGCCAACTATGCAGATGGAATTGACACTAGCTGGATCTGGGATGCAGACTTTGAGCAAATCACTGACATGGACAT TCCTG AAATCAACGCTGGCGGTGTTCGTCATTCTGAAATCGCTCGTCGCCTCCGAGTGACTGGCTATCCAGCTGAGAAAA TCACT GAAACGAGTAATCTGGAGCAAGTTCTCAAGACCATTGAGAATCAAGACTGCAAGCATGCCTATATTCTGGCAACT TATAC TGCCATGCTGGAATTTCGTGAACTGCTGGCTAGTCGTCAGATTGTTAGAAAGGAGATGAACTAA-3' (B) Streptococcus pneumoniae murF2 polypeptide sequence deduced from a polynucleotide sequence in this table [SEQ ID NO 2] NH 2 - MNLKTTLGLlLAGRSSHrrVLSRLGRGSTLPGKVALQFDKDILQNLAKNYEIVVVTGTNGKTLTTALTVGILKEλ/YG QVLTN PSGANMITGIATTFLTAKSSKTGKNIAVXEIDEASLSRICDYIQPSLFVITNIFRDQMDRFGEIYTTYNMI DAI RKVPT ATVLLNGDSPLFYKPTIPNPIEYFGFDLEKGPAQLAHYNTEGILCPDCQGILKYEHNTYANLGAYICEGCGCKRP DLDYR LTKLVELTNNRSRFVIDGQEYGIQIGGLYNIYNALAAVAIARFLGADSQLIKQGFDKSRAVFGRQETFHIGDKEC TLVLI KNPVGATQAIEMIK APYPFSLSVLLNANYADGIDTSWIWDADFEQITDMDIPEINAGGVRHSEIARRLRVTGYP AEKIT ETSNLEQVLKTIENQDCKHAYILATYTAMLEFRELLASRQIVRKEMN-COOH Deposited materials A deposit compπsing a Streptococcus pneumoniae 0100993 strain has been deposited with the National Collections of Industπal and Maπne Bacteπa Ltd (herein "NCIMB"), 23 St Machar Dπve, Aberdeen AB2 1RY, Scotland on 11 April 1996 and assigned deposit number 40794 The deposit was descπbed as Streptococcus pneumoniae 0100993 on deposit On 17 Apπl 1996 a Streptococcus pneumoniae 0100993 DNA library in E co was similarly deposited with the NCIMB and assigned deposit number 40800 The Streptococcus pneumoniae strain deposit is refeπed to herein as "the deposited strain" or as "the DNA of the deposited strain " The deposited strain compπses a full length murF2 gene The sequence of the polynucleotides compπsed in the deposited strain, as well as the amino acid sequence of any polypeptide encoded thereby, are controlling in the event of any conflict with am descπption of sequences herein The deposit of the deposited strain has been made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for Purposes of Patent Procedure The deposited strain will be irrevocably and without restπction or condition released to the public upon the issuance of a patent The deposited strain is provided merely as convenience to those of skill in the art and is not an admission that a deposit is required for enablement. such as that required under 35 U S C §112 A license may be required to make, use or sell the deposited strain, and compounds deπved therefrom, and no such license is hereby granted In one aspect of the invention there is provided an isolated nucleic acid molecule encoding a mature polypeptide expressible by the Streptococcus pneumoniae 0100993 strain, which polypeptide is compπsed in the deposited strain Further provided by the invention are murF2 polynucleotide sequences in the deposited strain, such as DNA and RNA, and amino acid sequences encoded thereby Also provided by the invention are murF2 polypeptide and polynucleotide sequences isolated from the deposited strain Polypeptides MurF2 polypeptide of the mvention is substantially phylogenetically related to other proteins of the mur family In one aspect of the mvention there are provided polypeptides of Streptococcus pneumoniae referred to herem as "murF2" and "murF2 polypeptides" as well as biologically, diagnostically. prophylactically, clinically or therapeutically useful vaπants thereof, and compositions compπsmg the same Among the particularly prefeπed embodiments of the mvention are vaπants of murF2 polypeptide encoded by naturally occurring alleles of a murF2 gene The present mvention further provides for an isolated polypeptide that (a) comprises or consists of an ammo acid sequence that has at least 95% identity, most preferably at least 97-99% or exact identity, to that of SEQ ID NO 2 over the entire length of SEQ ID NO 2, (b) a polypeptide encoded by an isolated polynucleotide comprising or consisting of a polynucleotide sequence that has at least 95% identity, even more preferably at least 97-99% or exact identity to SEQ ID NO 1 over the entire length of SEQ ID NO 1 , (c) a polypeptide encoded by an isolated polynucleotide comprising or consisting of a polynucleotide sequence encoding a polypeptide that has at least 95% identity, even more preferably at least 97-99% or exact identity, to the amino acid sequence of SEQ ID NO 2, over the entire length of SEQ ID NO 2 The polypeptides of the mvention include a polypeptide of Table 1 [SEQ ID NO 2] (in particular a mature polypeptide) as well as polypeptides and fragments, particularly those that has a biological activity of murF2, and also those that have at least 95% identity to a polypeptide of Table 1 [SEQ ID NO 2] and also include portions of such polypeptides with such portion of the polypeptide generally compπsmg at least 30 ammo acids and more preferably at least 50 ammo acids The mvention also mcludes a polypeptide consisting of or compπsmg a polypeptide of the formula X-(Rι) m -(R 2 )-(R 3 ) n -Y wherem, at the ammo terminus, X is hydrogen, a metal or any other moiety descπbed herem for modified polypeptides, and at the carboxyl terminus, Y is hydrogen, a metal or any other moiety descπbed herem for modified polypeptides, R j and R3 are any ammo acid residue or modified ammo acid residue, m is an mteger between 1 and 1000 or zero, n is an mteger between 1 and 1000 or zero, and R 2 is an ammo acid sequence of the mvention. particularly an ammo acid sequence selected from Table 1 or modified forms thereof In the formula above, R 2 is oπented so that its ammo terminal ammo acid residue is at the left, covalently bound to Rj and its carboxy terminal ammo acid residue is at the πght. covalently bound to R3 Any stretch of ammo acid residues denoted bv either Ri or R3, where m and/or n is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer Other prefeπed embodiments of the mvention are provided where m is an mteger between 1 and 50. 100 or 500, and n is an mteger between 1 and 50, 100, or 500 It is most preferred that a polypeptide of the mvention is deπved from Streptococcus pneumoniae. however, it may preferably be obtamed from other organisms of the same taxonomic genus A polypeptide of the mvention may also be obtamed, for example from organisms of the same taxonomic family or order A fragment is a vaπant polypeptide having an ammo acid sequence that is entirely the same as part but not all of any ammo acid sequence of any polypeptide of the mvention As with murF2 polypeptides, fragments may be "free-standing," or compπsed withm a larger polypeptide of which they form a part or region, most preferably as a smgle continuous region m a smgle larger polypeptide Prefeπed fragments mclude, for example, truncation polypeptides having a portion of an ammo acid sequence of Table 1 [SEQ ID NO 2], or of vaπants thereof, such as a contmuous seπes of residues that mcludes an ammo- and/or carboxyl-terminal ammo acid sequence Degradation forms of the polypeptides of the mvention produced by or m a host cell, particularly a Streptococcus pneumoniae, are also preferred Further preferred are fragments characterized by structural or functional attπbutes such as fragments that compπse alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and tum-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigeruc index regions Further prefeπed fragments mclude an isolated polypeptide comprising an ammo acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous amino acids from the amino acid sequence of SEQ ID NO 2, or an isolated polypeptide comprising an amino acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous amino acids truncated or deleted from the amino acid sequence of SEQ ID NO 2 Fragments of the polypeptides of the mvention may be employed for producmg the coπespondng full-length polypeptide by peptide synthesis, therefore, these vaπants may be employed as intermediates for producmg the full-length polypeptides of the mvention Polynucleotides It is an object of the mvention to provide polynucleotides that encode murF2 polypeptides, particularly polynucleotides that encode a polvpeptide herem designated murF2 In a particularly prefeπed embodiment of the mvention the polynucleotide compπses a region encoding murF2 polypeptides compπsmg a sequence set out m Table 1 [SEQ ID NO 1] that mcludes a full length gene, or a variant thereof The Applicants believe that this full length gene is essential to the growth and/or survival of an organism that possesses it. such as Streptococcus pneumoniae As a further aspect of the mvention there are provided isolated nucleic acid molecules encoding and/or expressmg murF2 polypeptides and polynucleotides, particularly Streptococcus pneumoniae murF2 polypeptides and polynucleotides, including, for example, unprocessed RNAs, πbozyme RNAs, niRNAs, cDNAs, genomic DNAs, B- and Z-DNAs Further embodiments of the mvention mclude biologically, diagnostically, prophylactically, clinicaUy or therapeutically useful polynucleotides and polypeptides, and vaπants thereof, and compositions compπsmg the same Another aspect of the mvention relates to isolated polynucleotides, including at least one full length gene, that encodes a murF2 polypeptide having a deduced ammo acid sequence of Table 1 [SEQ ID NO 2] and polynucleotides closely related thereto and vaπants thereof In another particularly preferred embodiment of the invention there is a murF2 polypeptide from Streptococcus pneumoniae comprising or consisting of an amino acid sequence of Table 1 [SEQ ID NO 2], or a variant thereof Usmg the information provided herein, such as a polynucleotide sequence set out m Table 1 [SEQ ID NO 1], a polynucleotide of the mvention encoding murF2 polypeptide may be obtamed usmg standard cloning and screening methods, such as those for cloning and sequencmg chromosomal DNA fragments from bacteπa using Streptococcus pneumoniae 0100993 cells as starting mateπal, followed by obtaining a full length clone For example, to obtain a polynucleotide sequence of the invention, such as a polynucleotide sequence given m Table 1 [SEQ ID NO 1], typically a hbrar> of clones of chromosomal DNA of Streptococcus pneumoniae 0100993 in E colt or some other suitable host is probed with a radiolabeled ohgonucleotide, preferably a 17-mer or longer, derived from a partial sequence Clones carrying DNA identical to that of the probe can then be distinguished usmg stringent hybridization conditions By sequencing the individual clones thus identified by hybridization with sequencing primers designed from the original polypeptide or polynucleotide sequence it is then possible to extend the polynucleotide sequence in both directions to determine a full length gene sequence Conveniently, such sequencing is performed, for example, using denatured double stranded DNA prepared from a plasmid clone Suitable techniques are descπbed by Ma atis, T . Fπtsch, E F and Sambrook et al . MOLECULAR CLONING, A LABORATORY MANUAL, 2nd Ed , Cold Spring Harbor Laboratory Press. Cold Spring Harbor, New York (1989) (see in particular Screening By Hybridization 1 90 and Sequencmg Denatured Double-Stranded DNA Templates 13 70) Direct genomic DNA sequencmg may also be performed to obtain a full length gene sequence Illustrative of the mvention, each polynucleotide set out m Table 1 [SEQ ID NO 1] was discovered m a DNA library deπved from Streptococcus pneumoniae 0100993 Moreover, each DNA sequence set out m Table 1 [SEQ ID NO 1] contains an open readmg frame encoding a protein having about the number of ammo acid residues set forth m Table 1 [SEQ ID NO 2] with a deduced molecular weight that can be calculated usmg ammo acid residue molecular weight values well known to those skilled m the art The polynucleotide of SEQ ID NO 1, between nucleotide number 1 and the stop codon that begins at nucleotide number 1342 of SEQ ID NO 1, encodes the polypeptide of SEQ ID NO 2 In a further aspect, the present mvention provides for an isolated polynucleotide compns g or consisting of (a) a polynucleotide sequence that has at least 95% identity, even more preferably at least 97-99% or exact identity to SEQ ID NO 1 over the entire length of SEQ ID NO 1. or the entire length of that portion of SEQ ID NO 1 which encodes SEQ ID NO 2, (b) a polynucleotide sequence encoding a polypeptide that has at least 95% identity, even more preferably at least 97%, still more preferably at least 99%, yet still more preferably at least 99 5% or 100% exact, to the ammo acid sequence of SEQ ID NO 2, over the entire length of SEQ ID NO 2 A polynucleotide encoding a polypeptide of the present mvention, including homologs and orthologs from species other than Streptococcus pneumoniae, may be obtained by a process that compπses the steps of screening an appropπate library under stringent hybπdization conditions with a labeled or detectable probe consisting of or compπsmg the sequence of SEQ ID NO 1 or a fragment thereof, and isolating a full-length gene and or genomic clones compπsmg said polynucleotide sequence The mvention provides a polynucleotide sequence identical over its entire length to a codmg sequence (open reading frame) m Table 1 [SEQ ID NO 1] Also provided by the mvention is a coding sequence for a mature polypeptide or a fragment thereof, by itself as well as a codmg sequence for a mature polypeptide or a fragment m readmg frame with another codmg sequence, such as a sequence encoding a leader or secretory sequence, a pre-, or pro- or prepro-protein sequence The polynucleotide of the mvention may also compπse at least one non-coding sequence, including for example, but not limited to at least one non-coding 5' and 3' sequence, such as the transcπbed but non-translated sequences termination signals (such as rho-dependent and rho-mdependent termination signals), nbosome binding sites, Kozak sequences, sequences that stabilize niRNA, mtrons. and polyadenylation signals The polynucleotide sequence may also compπse additional codmg sequence encoding additional ammo acids For example, a marker sequence that facilitates puπfication of a fused polypeptide can be encoded In certain embodiments of the mvention, the marker sequence is a hexa-histidine peptide, as provided m the pQE vector (Qiagen, Inc ) and descπbed m Gentz et al , Proc Natl Acad Sc , USA 86 821-824 (1989), or an HA peptide tag (Wilson et al , Cell 37 767 (1984), both of that may be useful m purifying polypeptide sequence fused to them Polynucleotides of the mvention also mclude, but are not limited to, polynucleotides compπsmg a structural gene and its naturally associated sequences that control gene expression A prefeπed embodiment of the mvention is a polynucleotide of consisting of or compπsmg nucleotide 1 to the nucleotide immediately upstream of or including nucleotide 1342 set forth m SEQ ID NO 1 of Table 1. both of that encode a murF2 polypeptide The mvention also mcludes a polynucleotide consisting of or compπsmg a polynucleotide of the formula X-(R 1 ) m -(R 2 )-(R 3 ) n -Y where , at the 5' end of the molecule. X is hydrogen, a metal or a modified nucleotide residue, or together with Y defines a covalent bond, and at the 3' end of the molecule, Y is hydrogen, a metal, or a modified nucleotide residue, or together with X defines the covalent bond, each occurrence of Rj and R3 is independently any nucleic acid residue or modified nucleic acid residue, m is an integer between 1 and 3000 or zero , n is an mteger between 1 and 3000 or zero, and R 2 is a nucleic acid sequence or modified nucleic acid sequence of the mvention, particularly a nucleic acid sequence selected from Table 1 or a modified nucleic acid sequence thereof In the polynucleotide formula above, R is oriented so that its 5' end nucleic acid residue is at the left, bound to R j and its 3' end nucleic acid residue is at the right, bound to R3 Any stretch of nucleic acid residues denoted by either R and/or R 2 , where m and/or n is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer Where, m a preferred embodiment, X and Y together define a covalent bond, the polynucleotide of the above formula is a closed, circular polynucleotide, that can be a double-stranded polynucleotide wherein the formula shows a first strand to which the second strand is complementary In another preferred embodiment m and/or n is an integer between 1 and 1000. Other prefeπed embodiments of the mvention are provided where m is an mteger between 1 and 50, 100 or 500, and n is an mteger between 1 and 50. 100, or 500 It is most preferred that a polynucleotide of the mvention is deπved from Streptococcus pneumoniae. however, it may preferably be obtamed from other organisms of the same taxonomic genus A polynucleotide of the mvention may also be obtamed. for example, from organisms of the same taxonomic family or order The term "polynucleotide encoding a polypeptide" as used herem encompasses polynucleoudes that mclude a sequence encoding a polypeptide of the mvention, particularly a bacteπal polypeptide and more particularly a polypeptide of the Streptococcus pneumoniae murF2 having an ammo acid sequence set out m Table 1 [SEQ ID NO 2] The term also encompasses polynucleotides that mclude a smgle continuous region or discontinuous regions encoding the polypeptide (for example, polynucleotides interrupted by integrated phage, an mtegrated insertion sequence an mtegrated vector sequence, an integrated transposon sequence, or due to RNA editing or genomic DNA reorganization) together with additional regions, that also may compπse codmg and/or non-coding sequences The mvention further relates to vaπants of the polynucleotides descπbed herem that encode vaπants of a polypeptide having a deduced amino acid sequence of Table 1 [SEQ ID NO 2] Fragments of polynucleotides of the mvention may be used, for example, to synthesize full-length polynucleotides of the mvention Further particularly prefeπed embodiments are polynucleotides encoding murF2 vaπants, that have the ammo acid sequence of murF2 polypeptide of Table 1 [SEQ ID NO 2] in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no ammo acid residues are substituted, modified, deleted and or added, m any combination Especially prefeπed among these are silent substitutions, additions and deletions, that do not alter the properties and activities of murF2 polypeptide Preferred isolated polynucleotide embodiments also mclude polynucleotide fragments, such as a polynucleotide comprising a nuclic acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous nucleic acids from the polynucleotide sequence of SEQ ID NO: l, or an polynucleotide comprising a nucleic acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous nucleic acids truncated or deleted from the 5' and/or 3' end of the polynucleotide sequence of SEQ ID NO: l . Further prefeπed embodiments of the mvention are polynucleotides that are at least 95% or 97% identical over their entire length to a polynucleotide encoding murF2 polypeptide having an ammo acid sequence set out m Table 1 [SEQ ID NO 2], and polynucleotides that are complementary to such polynucleotides Most highly prefeπed are polynucleotides that compπse a region that is at least 95% are especially preferred Furthermore, those with at least 97% are highly prefeπed among those with at least 95%, and among these those with at least 98% and at least 99% are particularly highly prefeπed, with at least 99% bemg the more preferred Preferred embodiments are polynucleotides encoding polypeptides that retain substantially the same biological function or activity as a mature polypeptide encoded by a DNA of Table 1 [SEQ ID NO 1] In accordance with certain preferred embodiments of this mvention there are provided polynucleotides that hybπdize, particularly under stringent conditions, to murF2 polynucleotide sequences, such as those polynucleoudes m Table 1 The mvention further relates to polynucleotides that hybπdize to the polynucleotide sequences provided herem In this regard, the mvention especially relates to polynucleotides that hybπdize under stringent conditions to the polynucleotides descπbed herem As herem used, the terms "stringent conditions" and "stringent hybπdization conditions" mean hybπdization occurring only if there is at least 95% and preferably at least 97% identity between the sequences A specific example of stπngent hybridization conditions is overnight incubation at 42°C m a solution comprising 50% formamide, 5x SSC (150mM NaCl, 15mM tπsodium citrate), 50 mM sodium phosphate (pH7 6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml of denatured, sheared salmon sperm DNA, followed by washing the hybridization support m 0 lx SSC at about 65°C Hybridization and wash conditions are well known and exemplified in Sambrook, et al . Molecular Cloning A Laboratory Manual, Second Edition, Cold Spring Harbor, N Y , (1989), particularly Chapter 11 therein Solution hybridization may also be used with the polynucleotide sequences provided by the invention The invention also provides a polynucleotide consisting of or comprising a polynucleotide sequence obtained by screening an appropnate library compπsing a complete gene for a polynucleotide sequence set forth in SEQ ID NO 1 under stπngent hybridization conditions with a probe having the sequence of said polynucleotide sequence set forth in SEQ ID NO 1 or a fragment thereof, and isolating said polynucleotide sequence Fragments useful for obtaining such a polynucleotide include, for example, probes and primers fully described elsewhere herein As discussed elsewhere herem regarding polynucleotide assays of the mvention, for instance, the polynucleotides of the mvention, may be used as a hybπdization probe for RNA, cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encoding murF2 and to isolate cDNA and genomic clones of other genes that have a high identity, particularly high sequence identity, to a murF2 gene Such probes generally will compπse at least 15 nucleotide residues or base pairs Preferably, such probes will have at least 30 nucleotide residues or base pairs and may have at least 50 nucleotide residues or base pairs Particularly preferred probes will have at least 20 nucleotide residues or base pairs and will have lee than 30 nucleotide residues or base pairs A codmg region of a murF2 gene may be isolated by screening usmg a DNA sequence provided m Table 1 [SEQ ID NO 1] to synthesize an o gonucleotide probe A labeled o gonucleoude having a sequence complementary to that of a gene of the mvention is then used to screen a library of cDNA, genomic DNA or mRNA to determine which members of the library the probe hybndizes to There are several methods available and well known to those skilled in the art to obtain full- length DNAs, or extend short DNAs, for example those based on the method of Rapid Amplification of cDNA ends (RACE) (see, for example, Frohman, et al , PNAS USA 85 8998-9002, 1988) Recent modifications of the technique, exemplified by the Marathon™ technology (Clontech Laboratories Inc ) for example, have significantly simplified the search for longer cDNAs In the Marathon™ technology, cDNAs have been prepared from mRNA extracted from a chosen tissue and an 'adaptor' sequence hgated onto each end Nucleic acid amplification (PCR) is then earned out to amplify the "missing" 5' end of the DNA using a combination of gene specific and adaptor specific ohgonucleotide primers The PCR reaction is then repeated using "nested" primers, that is, primers designed to anneal withm the amplified product (typically an adaptor specific pnmer that anneals further 3' in the adaptor sequence and a gene specific primer that anneals further 5' m the selected gene sequence) The products of this reaction can then be analyzed by DNA sequencmg and a full-length DNA constructed either by joining the product directly to the existing DNA to give a complete sequence, or carrying out a separate full- length PCR using the new sequence information for the design of the 5' pnmer The polynucleotides and polypeptides of the mvention may be employed, for example, as research reagents and mateπals for discovery of treatments of and diagnostics for diseases, particularly human diseases, as further discussed herem relatmg to polynucleotide assays The polynucleotides of the mvention that are ohgonucleotides derived from a sequence of Table 1 [SEQ ID NOS 1 or 2] may be used in the processes herem as described, but preferably for PCR, to determine whether or not the polynucleotides identified herein m whole or m part are transcnbed in bacteria in infected tissue It is recognized that such sequences will also have utility in diagnosis of the stage of mfection and type of infection the pathogen has attained The mvention also provides polynucleotides that encode a polypeptide that is a mature protem plus additional ammo or carboxyl-terminal ammo acids, or ammo acids mteπor to a mature polypeptide (when a mature form has more than one polypeptide chain, for instance) Such sequences may play a role m processing of a protem from precursor to a mature form, may allow protem transport, may lengthen or shorten protem half-life or may facihtate manipulation of a protem for assay or production, among other things As generally is the case in vivo, the additional ammo acids may be processed away from a mature protem by cellular enzymes For each and every polynucleotide of the mvention there is provided a polynucleotide complementary to it It is prefeπed that these complementary polynucleotides are fully complementary to each polynucleotide with which they are complementary A precursor protem. having a mature form of the polypeptide fused to one or more prosequences may be an mactive form of the polypeptide When prosequences are removed such mactive precursors generally are activated Some or all of the prosequences may be removed before activation Generally, such precursors are called proproteins As will be recognized, the entire polypeptide encoded by an open readmg frame is often not required for activity Accordingly, it has become routme in molecular biology to map the boundaries of the primary structure required for activity with N-terminal and C-terminal deletion experiments These experiments utilize exonuclease digestion or convenient restnction sites to cleave codmg nucleic acid sequence For example, Promega (Madison, WI) sell an Erase-a-base™ system that uses Exonuclease HI designed to facilitate analysis of the deletion products (protocol available at www promega com) The digested endpomts can be repaired (e g , by gation to synthetic linkers) to the extent necessary to preserve an open readmg frame In this way. the nucleic acid of SEQ ID NO 1 readily provides contiguous fragments of SEQ ID NO 2 sufficient to provide an activity, such as an enzymatic, binding or antibody-inducing activity Nucleic acid sequences encoding such fragments of SEQ ID NO 2 and vaπants thereof as descπbed herem are withm the mvention, as are polypeptides so encoded In sum, a polynucleotide of the mvention may encode a mature protem, a mature protem plus a leader sequence (which may be refeπed to as a preprotem), a precursor of a mature protem havmg one or more prosequences that are not the leader sequences of a preprotem, or a preproprotem, that is a precursor to a proprotem. havmg a leader sequence and one or more prosequences, that generally are removed during processmg steps that produce active and mature forms of the polypeptide Vectors, Host Cells, Expression Systems The mvention also relates to vectors that compπse a polynucleotide or polynucleotides of the mvention, host cells that are genetically engmeered with vectors of the mvention and the production of polypeptides of the mvention by recombinant techniques Cell-free translation systems can also be employed to produce such proteins usmg RNAs deπved from the DNA constructs of the mvention Recombinant polypeptides of the present mvention may be prepared by processes well known m those skilled m the art from genetically engmeered host cells compπsmg expression systems Accordingly, in a further aspect, the present mvention relates to expression systems that compπse a polynucleoude or polynucleotides of the present mvention, to host cells that are genetically engmeered with such expression systems, and to the production of polypeptides of the mvention by recombinant techniques For recombinant production of the polypeptides of the mvention, host cells can be genetically engmeered to incorporate expression systems or portions thereof or polynucleotides of the mvention Introducnon of a polynucleotide mto the host cell can be effected by methods descπbed m many standard laboratory manuals, such as Davis, et al , BASIC METHODS IN MOLECULAR BIOLOGY, (1986) and Sambrook. et al , MOLECULAR CLONING A LABORATORY MANUAL, 2nd Ed , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N Y (1989), such as, calcium phosphate transfection. DEAE-dextran mediated transfection, transvection, microinjection, canonic lipid-mediated transfection, electroporation. transduction. scrape loading, ballistic mtroduction and infection Representative examples of appropnate hosts mclude bacteπal cells, such as cells of streptococci, staphylococci, enterococci E coh, streptomyces, cyanobacteπa, Bacillus subtihs, and Streptococcus pneumoniae. fungal cells, such as cells of a yeast, Kluveromyces, Saccharomyces, a basidiomycete. Candida albicans and Aspergύlus. insect cells such as cells of Drosophi la S2 and Spodoptera Sf9, animal cells such as CHO, COS, HeLa. C127, 3T3, BHK, 293, CV-1 and Bowes melanoma cells, and plant cells, such as cells of a gymnosperm or angiosperm A great vanety of expression systems can be used to produce the polypeptides of the mvention Such vectors mclude. among others, chromosomal-, episomal- and virus-deπved vectors, for example, vectors deπved from bacteπal plasmids, from bactenophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses. papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses, picornaviruses and retroviruses, and vectors denved from combinations thereof, such as those deπved from plasmid and bactenophage genetic elements, such as cosmids and phageπuds The expression system constructs may compnse control regions that regulate as well as engender expression Generally, any system or vector suitable to maintain, propagate or express polynucleotides and or to express a polypeptide m a host may be used for expression m this regard The appropnate DNA sequence may be inserted mto the expression system by any of a vanety of well-known and routme techniques, such as, for example, those set forth m Sambrook et al , MOLECULAR CLONING, A LABORATORY MANUAL, (supra) In recombinant expression systems m eukaryotes. for secretion of a translated protem mto the lumen of the endoplasmic reticulum, mto the penplasmic space or mto the extracellular environment, appropnate secretion signals may be incorporated mto the expressed polypeptide These signals may be endogenous to the polypeptide or they may be heterologous signals Polypeptides of the mvention can be recovered and purified from recombinant cell cultures by well- known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic mteraction chromatography, affinity chromatography . hydroxylapatite chromatography. and lectm chromatography Most preferably, high performance liquid chromatography is employed for purification Well known techniques for refolding protem may be employed to regenerate active conformation when the polypeptide is denatured during isolation and or punfication Diagnostic, Prognostic, Serotyping and Mutation Assays This mvention is also related to the use of murF2 polynucleotides and polypeptides of the mvention for use as diagnostic reagents Detection of murF2 polynucleotides and/or polypeptides m a eukaryote. particularly a mammal, and especially a human, will provide a diagnostic method for diagnosis of disease, staging of disease or response of an infectious organism to drugs Eukaryotes. particularly mammals, and especially humans, particularly those infected or suspected to be infected with an organism compπsmg the murF2 gene or protem. may be detected at the nucleic acid or ammo acid level by a vanety of well known techniques as well as by methods provided herem Polypeptides and polynucleotides for prognosis, diagnosis or other analysis may be obtamed from a putatively infected and/or infected individual's bodily mateπals Polynucleotides from any of these sources, particularly DNA or RNA, may be used directly for detection or may be amplified enzymatically by usmg PCR or any other amplification technique pπor to analysis RNA, particularly mRNA, cDNA and genomic DNA may also be used m the same ways Usmg amplification, charactenzation of the species and stram of infectious or resident organism present m an individual, may be made by an analysis of the genotype of a selected polynucleotide of the organism Deletions and insertions can be detected by a change m size of the amplified product m compaπson to a genotype of a reference sequence selected from a related organism, preferably a different species of the same genus or a different stram of the same species Pomt mutations can be identified by hybπdizmg amplified DNA to labeled murF2 polynucleotide sequences Perfectly or significantly matched sequences can be distinguished from imperfectly or more significantly mismatched duplexes by DNase or RNase digestion, for DNA or RNA respectively, or by detectmg differences m meltmg temperatures or renaturation kmetics Polynucleotide sequence differences may also be detected by alterations m the electrophoretic mobility of polynucleotide fragments m gels as compared to a reference sequence This may be earned out with or without denaturing agents Polynucleotide differences may also be detected by direct DNA or RNA sequencmg See, for example, Myers et al , Science, 230 1242 (1985) Sequence changes at specific locations also may be revealed by nuclease protection assays, such as RNase, VI and SI protection assay or a chemical cleavage method See, for example, Cotton et al , Proc Natl Acad Sci , USA, 85 4397-4401 (1985) In another embodiment, an aπay of oligonucleotides probes compπsmg murF2 nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of. for example, genetic mutations, serotype, taxonomic classification or identification Anay technology methods are well known and have general applicability and can be used to address a vanety of questions in molecula genetics including gene expression, genetic linkage, and genetic vanability (see, for example. Chee et al , Science, 274 610 (1996)) Thus in another aspect, the present invention relates to a diagnostic kit that comprises (a) a polynucleotide of the present invention, preferably the nucleotide sequence of SEQ ID NO 1, or a fragment thereof , (b) a nucleotide sequence complementary to that of (a), (c) a polypeptide of the present invention, preferably the polypeptide of SEQ ID NO 2 or a fragment thereof, or (d) an antibody to a polypeptide of the present invention, preferably to the polypeptide of SEQ ID NO 2 It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component Such a kit will be of use in diagnosing a disease or susceptibility to a Disease, among others This mvention also relates to the use of polynucleotides of the present mvention as diagnostic reagents Detection of a mutated form of a polynucleotide of the mvention, preferable. SEQ ID NO 1, that is associated with a disease or pathogenicity will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, a prognosis of a course of disease, a determination of a stage of disease, or a susceptibility to a disease, that results from under-expression, over-expression or altered expression of the polynucleotide Organisms, particularly infectious organisms, carrying mutations m such polynucleotide may be detected at the polynucleotide level by a vanety of techmques, such as those descπbed elsewhere herem The differences in a polynucleotide and/or polypeptide sequence between organisms possessing a first phenotype and organisms possessing a different, second different phenotype can also be determined If a mutation is observed in some or all organisms possessing the first phenotype but not in any organisms possessing the second phenotype, then the mutation is likely to be the causative agent of the first phenotype Cells from an organism carrying mutations or polymorphisms (allehc vaπations) in a polynucleotide and/or polypeptide of the mvention may also be detected at the polynucleotide or polypeptide level by a vanety of techmques, to allow for serotypmg. for example For example, RT-PCR can be used to detect mutations m the RNA It is particularly prefened to use RT-PCR m conjunction with automated detection systems, such as, for example, GeneScan RNA, cDNA or genomic DNA may also be used for the same purpose, PCR As an example, PCR primers complementary to a polynucleotide encoding murF2 polypeptide can be used to identify and analyze mutations The mvention further provides these primers with 1, 2, 3 or 4 nucleotides removed from the 5' and/or the 3' end These primers may be used for, among other things, amplifymg murF2 DNA and/or RNA isolated from a sample deπved from an individual, such as a bodily mateπal The primers may be used to amplify a polynucleotide isolated from an infected individual, such that the polynucleotide may then be subject to vaπous techniques for elucidation of the polynucleotide sequence In this way, mutations m the polynucleotide sequence may be detected and used to diagnose and or prognose the infection or its stage or course, or to serotype and/or classify the infectious agent The mvention further provides a process for diagnosing, disease, preferably bacterial mfections, more preferably mfections caused by Streptococcus pneumoniae, comprising determining from a sample derived from an individual, such as a bodily material, an increased level of expression of polynucleotide having a sequence of Table 1 [SEQ ID NO 1] Increased or decreased expression of a murF2 polynucleotide can be measured usmg any on of the methods well known m the art for the quantitation of polynucleotides, such as, for example, amplification. PCR, RT-PCR, RNase protection, Northern blotting, spectrometry and other hybridization methods In addition, a diagnostic assay m accordance with the mvention for detecting over-expression of murF2 polypeptide compared to normal control tissue samples may be used to detect the presence of an infection, for example Assay techmques that can be used to determine levels of a murF2 polypeptide, m a sample denved from a host, such as a bodily mateπal, are well-known to those of skill m the art Such assay methods mclude radioimmunoassays, competitive-binding assays, Western Blot analysis, antibody sandwich assays, antibody detection and ELISA assays Antagonists and Agonists - Assays and Molecules Polypeptides and polynucleotides of the mvention may also be used to assess the binding of small molecule substrates and ligands m, for example, cells, cell-free preparations, chemical hbranes, and natural product mixtures These substrates and ligands may be natural substrates and ligands or may be structural or functional mimetics See, e g , Coligan et al , Current Protocols in Immunology 1(2) Chapter 5 (1991) Polypeptides and polynucleotides of the present mvention are responsible for many biological functions, including many disease states, m particular the Diseases herem mentioned It is therefore desirable to devise screening methods to identify compounds that agonize (e g , stimulate) or that antagonize (e g ,ιnhιbιt) the function of the polypeptide or polynucleotide Accordingly, in a further aspect, the present mvention provides for a method of screening compounds to identify those that agonize or that antagonize the function of a polypeptide or polynucleotide of the mvention, as well as related polypeptides and polynucleotides In general, agonists or antagonists (e g , inhibitors) may be employed for therapeutic and prophylactic purposes for such Diseases as herem mentioned Compounds may be identified from a vanety of sources, for example, cells, cell-free preparations, chemical hbranes, and natural product mixtures Such agonists and antagonists so-identified may be natural or modified substrates, ligands, receptors, enzymes, etc , as the case may be. of murF2 polypeptides and polynucleotides, or may be structural or functional mimetics thereof (see Coligan et al . Current Protocols in Immunology 1(2) Chapter 5 (1991)) The screening methods may simply measure the binding of a candidate compound to the polypeptide or polynucleotide, or to cells or membranes beanng the polypeptide or polynucleotide, or a fusion protein of the polypeptide by means of a label directly or indirectly associated with the candidate compound Alternatively, the screening method may involve competition with a labeled competitor Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide or polynucleotide, using detection systems appropriate to the cells comprising the polypeptide or polynucleotide Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed Constitutively active polypeptide and/or constitutively expressed polypeptides and polynucleotides may be employed in screening methods for inverse agomsts, m the absence of an agonist or antagonist, by testing whether the candidate compound results m inhibition of activation of the polypeptide or polynucleotide, as the case may be Further, the screening methods may simply comprise the steps of mixing a candidate compound with a solution compπsmg a polypeptide or polynucleotide of the present invention, to form a mixture, measuring murF2 polypeptide and/or polynucleotide activity in the mixture, and comparing the murF2 polypeptide and/or polynucleotide activity of the mixture to a standard Fusion proteins, such as those made from Fc portion and murF2 polypeptide. as herein described, can also be used for high-throughput screening assays to identify antagonists of the polypeptide of the present invention, as well as of phylogenetically and and/or functionally related polypeptides (see D Bennett et al . J Mol Recognition, 8 52-58 (1995), and K Johanson et al , J Biol Chem, 270(16) 9459-9471 (1995)) The polynucleotides. polypeptides and antibodies that bind to and/or interact with a polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and/or polypeptide in cells For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art This can be used to discover agents that may inhibit or enhance the production of polypeptide (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues The mvention also provides a method of screening compounds to identify those that enhance (agonist) or block (antagonist) the action of murF2 polypeptides or polynucleotides, particularly those compounds that are bactenstatic and/or bacteπcidal The method of screenmg may mvolve high-throughput techmques For example, to screen for agonists or antagonists, a synthetic reaction mix, a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, compnsmg murF2 polypeptide and a labeled substrate or ligand of such polypeptide is mcubated m the absence or the presence of a candidate molecule that may be a murF2 agomst or antagonist The ability of the candidate molecule to agonize or antagomze the murF2 polypeptide is reflected m decreased bmdmg of the labeled ligand or decreased production of product from such substrate Molecules that bmd gratuitously, i e , without mducmg the effects of murF2 polypeptide are most likely to be good antagonists Molecules that bmd well and, as the case may be. mcrease the rate of product production from substrate, mcrease signal transduction. or mcrease chemical channel activity are agonists Detection of the rate or level of, as the case may be, production of product from substrate, signal transduction. or chemical channel activity may be enhanced by usmg a reporter system Reporter systems that may be useful in this regard mclude but are not limited to coloπmetπc. labeled substrate converted mto product, a reporter gene that is responsive to changes m murF2 polynucleotide or polypeptide activity, and bmdmg assays known m the art Polypeptides of the invention may be used to identify membrane bound or soluble receptors, if any, for such polypeptide. through standard receptor binding techmques known in the art These techniques include, but are not limited to. ligand binding and crosshnking assays m which the polypeptide is labeled with a radioactive isotope (for instance, ->I), chemically modified (for instance, biotmylated), or fused to a peptide sequence suitable for detection or puπfication, and incubated with a source of the putative receptor (e g , cells, cell membranes, cell supernatants, tissue extracts, bodily materials) Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy These screening methods may also be used to identify agonists and antagonists of the polypeptide that compete with the binding of the polypeptide to its receptor(s), if any Standard methods for conducting such assays are well understood in the art The fluorescence polarization value for a fluorescently-tagged molecule depends on the rotational correlation time or tumbling rate Protein complexes, such as formed by murF2 polypeptide associating with another murF2 polypeptide or other polypeptide, labeled to comprise a fluorescently-labeled molecule will have higher polarization values than a fluorescently labeled monomeπc protem It is preferred that this method be used to characterize small molecules that disrupt polypeptide complexes Fluorescence energy transfer may also be used charactenze small molecules that interfere with the formation of murF2 polypeptide duners, tπmers, tetramers or higher order structures, or structures formed by murF2 polypeptide bound to another polypeptide MurF2 polypeptide can be labeled with both a donor and acceptor fluorophore Upon mixmg of the two labeled species and excitation of the donor fluorophore. fluorescence energy transfer can be detected by observing fluorescence of the acceptor Compounds that block dimeπzation will inhibit fluorescence energy transfer Surface plasmon resonance can be used to monitor the effect of small molecules on murF2 polypeptide self-association as well as an association of murF2 polypeptide and another polypeptide or small molecule MurF2 polypeptide can be coupled to a sensor chip at low site density such that covalently bound molecules will be monomeπc Solution protem can then passed over the murF2 polypeptide -coated surface and specific bmdmg can be detected in real-time by monitoring the change m resonance angle caused by a change m local refractive index This technique can be used to characterize the effect of small molecules on kinetic rates and equilibrium binding constants for murF2 polypeptide self-association as well as an association of murF2 polypeptide and another polypeptide or small molecule A scintillation proximity assay may be used to characterize the interaction between an association of murF2 polypeptide with another murF2 polypeptide or a different polypeptide MurF2 polypeptide can be coupled to a scintillation-filled bead Addition of radio-labeled murF2 polypeptide results in bindmg where the radioactive source molecule is in close proximity to the scintillation fluid Thus, signal is emitted upon murF2 polypeptide binding and compounds that prevent murF2 polypeptide self-association or an association of murF2 polypeptide and another polypeptide or small molecule will dimmish signal In other embodiments of the mvention there are provided methods for identifying compounds that bmd to or otherwise interact with and inhibit or activate an activity or expression of a polypeptide and/or polynucleotide of the mvention compnsmg contactmg a polypeptide and/or polynucleotide of the mvention with a compound to be screened under conditions to permit bmdmg to or other interaction between the compound and the polypeptide and or polynucleotide to assess the bmdmg to or other mteraction with the compound, such bmdmg or mteraction preferably being associated with a second component capable of providing a detectable signal m response to the bmdmg or mteraction of the polypeptide and/or polynucleotide with the compound, and deteimining whether the compound bmds to or otherwise interacts with and activates or inhibits an activity or expression of the polypeptide and/or polynucleotide by detecting the presence or absence of a signal generated from the bmdmg or mteraction of the compound with the polypeptide and/or polynucleotide Another example of an assay for murF2 agonists is a competitive assay that combmes murF2 and a potential agomst with murF2-bιndιng molecules, recombinant murF2 bmdmg molecules, natural substrates or ligands. or substrate or ligand mimetics, under appropnate conditions for a competitive inhibition assay MurF2 can be labeled, such as by radioactivity or a colonmetπc compound, such that the number of murF2 molecules bound to a bmdmg molecule or converted to product can be determined accurately to assess the effectiveness of the potential antagonist It will be readily appreciated by the skilled artisan that a polypeptide and/or polynucleotide of the present mvention may also be used m a method for the structure-based design of an agonist or antagonist of the polypeptide and/or polynucleotide. by (a) determining in the first instance the three- dimensional structure of the polypeptide and or polynucleotide, or complexes thereof, (b) deducing the three-dimensional structure for the likely reactive sιte(s), binding sιte(s) or motιf(s) of an agonist or antagonist, (c) synthesizing candidate compounds that are predicted to bmd to or react with the deduced binding sιte(s). reactive sιte(s), and/or motif(s), and (d) testing whether the candidate compounds are indeed agonists or antagonists It will be further appreciated that this will normally be an iterative process, and this iterative process may be performed usmg automated and computer-controlled steps In a further aspect, the present mvention provides methods of treatmg abnormal conditions such as, for instance, a Disease, related to either an excess of, an under-expression of, an elevated activity of, or a decreased activity of murF2 polypeptide and/or polynucleotide If the expression and/or activity of the polypeptide and/or polynucleotide is m excess, several approaches are available One approach compnses administering to an mdividual m need thereof an inhibitor compound (antagonist) as herem descnbed, optionally m combination with a pharmaceutically acceptable earner, m an amount effective to inhibit the function and/or expression of the polypeptide and/or polynucleotide, such as. for example, by blockmg the bmdmg of ligands, substrates, receptors, enzymes, etc , or by inhibiting a second signal, and thereby alleviating the abnormal condition In another approach, soluble forms of the polypeptides still capable of bindmg the ligand, substrate, enzymes, receptors, etc in competition with endogenous polypeptide and or polynucleotide may be administered Typical examples of such competitors include fragments of the murF2 polypeptide and/or polypeptide In still another approach, expression of the gene encoding endogenous murF2 polypeptide can be inhibited using expression blocking techniques This blocking may be targeted against any step in gene expression, but is preferably targeted against transcription and/or translation An examples of a known technique of this sort mvolve the use of antisense sequences, either internally generated or separately administered (see, for example, O'Connor, J Neurochem (1991) 56 560 m Ohgodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988)) Alternatively, ohgonucleotides that form triple helices with the gene can be supplied (see, for example, Lee et al , Nucleic Acids Res (1979) 6 3073, Cooney et al , Science (1988) 241 456, Dervan et al , Science (1991) 251 1360) These ohgomers can be administered per se or the relevant ohgomers can be expressed in vivo Each of the polynucleotide sequences provided herein may be used in the discovery and development of antibacterial compounds The encoded protein, upon expression, can be used as a target for the screening of antibacterial drugs Additionally, the polynucleotide sequences encoding the ammo termmal regions of the encoded protem or Shine-Delgarno or other translation facilitating sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the codmg sequence of interest The invention also provides the use of the polypeptide, polynucleotide. agonist or antagonist of the invention to interfere with the initial physical interaction between a pathogen or pathogens and a eukaryotic, preferab mammalian, host responsible for sequelae of infection In particular, the molecules of the invention may be used in the prevention of adhesion of bacteria, m particular gram positive and/or gram negative bactena, to eukaryotic, preferably mammalian, extracellular matrix proteins on in-dwelling devices or to extracellular matrix proteins m wounds, to block bacterial adhesion between eukaryotic, preferably mammalian, extracellular matrix proteins and bacterial murF2 proteins that mediate tissue damage and/or, to block the normal progression of pathogenesis m infections initiated other than by the implantation of m-dwelling devices or by other surgical techmques In accordance with yet another aspect of the mvention, there are provided murF2 agonists and antagonists, preferably bacteπstatic or bacteπcidal agonists and antagonists The antagonists and agonists of the mvention may be employed, for instance, to prevent, inhibit and/or treat diseases Hehcobacter pylori (herein "H pylori") bacteria infect the stomachs of over one-third of the world's population causing stomach cancer, ulcers, and gastritis (International Agency for Research on Cancer (1994) Schistosomes, Liver Flukes and Hehcobacter Pylori (International Agency for Research on Cancer, Lyon. France, http //www uicc ch ecp/ecp2904 htm) Moreover, the International Agency for Research on Cancer recently recognized a cause-and-effect relationship between H pylori and gastric adenocarcinoma, classifying the bacteπum as a Group I (definite) carcinogen Preferred antimicrobial compounds of the invention (agonists and antagonists of murF2 polypeptides and/or polynucleotides) found using screens provided by the invention, or known in the art, particularly narrow-spectrum antibiotics, should be useful in the treatment of H pylori infection Such treatment should decrease the advent of H pylori -mduced cancers, such as gastrointestinal carcinoma Such treatment should also prevent, inhibit and/or cure gastric ulcers and gastritis All publications and references, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference m their entirety as if each individual publication or reference were specifically and individually indicated to be incorporated by reference herein as being fully set forth Any patent application to which this application claims priority is also incorporated by reference herein m its entirety in the manner descnbed above for publications and references GLOSSARY The following definitions are provided to facilitate understanding of certain terms used frequently herem "Bodily matenal(s) means any matenal deπved from an individual or from an organism infecting, infesting or inhabiting an mdividual, including but not limited to. cells, tissues and waste, such as, bone, blood, serum, cerebrospmal fluid, semen, saliva, muscle, cartilage, organ tissue, skin, urine, stool or autopsy mateπals "Dιsease(s)" means any disease caused by or related to infection by a bactena, including , for example, otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospmal fluid "Host cell(s)" is a cell that has been introduced (e g , transformed or transfected) or is capable of introduction (e g , transformation or transfection) by an exogenous polynucleotide sequence "Identity," as known m the art. is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as the case may be, as determined by comparing the sequences In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be. as determined by the match between stnngs of such sequences "Identity" can be readily calculated by known methods, mcluding but not limited to those described in (Computational Molecular Biology. Lesk. A M , ed , Oxford University Press, New York, 1988, Biocomputing Informatics and Genome Projects, Smith, D W , ed . Academic Press. New York, 1993, Computer Analysis of Sequence Data. Part I, Griffin, A M , and Griffin, H G , eds , Humana Press, New Jersey. 1994, Sequence Analysis in Molecular Biology, von Heinje, G . Academic Press, 1987, and Sequence Analysis Primer. Gnbskov, M and Devereux. J , eds , M Stockton Press, New York, 1991. and Caπllo, H , and Lipman. D . SIAM J Applied Math , 48 1073 (1988) Methods to determine identity are designed to give the largest match between the sequences tested Moreover, methods to determine identity are codified m publicly available computer programs Computer program methods to determine identity between two sequences include, but are not limited to, the GCG program package (Devereux, J , et al , Nucleic Acids Research 12(1) 387 (1984)), BLASTP. BLASTN, and FASTA (Altschul, S F et al . J Molec Biol 215 403-410 (1990) The BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S , et al , NCBI NLM NIH Bethesda, MD 20894, Altschul, S , et l . J Mol Biol 215 403-410 (1990) The well known Smith Waterman algorithm may also be used to determine identity Parameters for polypeptide sequence comparison include the following Algorithm Needleman and Wunsch, J Mol Biol 48 443-453 (1970) Comparison matrix BLOSSUM62 from Hentikoff and Hentikoff. Proc Natl Acad Sci USA 89 10915-10919 (1992) Gap Penalty 12 Gap Length Penalty 4 A program useful with these parameters is publicly available as the "gap" program from Genetics Computer Group, Madison WI The aforementioned parameters are the default parameters for peptide comparisons (along with no penalty for end gaps) Parameters for polynucleotide comparison mclude the following Algonthm Needleman and Wunsc , J Mol Biol 48 443-453 (1970) Comparison matrix matches = +10, mismatch = 0 Gap Penalty 50 Gap Length Penalty 3 Available as The "gap" program from Genetics Computer Group, Madison WI These are the default parameters for nucleic acid comparisons A preferred meanmg for "identity" for polynucleotides and polypeptides, as the case may be, are provided in (1) and (2) below (1) Polynucleotide embodiments further mclude an isolated polynucleotide comprising a polynucleotide sequence having at least a 95, 97, 99, 99 5 or 100% identity to the reference sequence of SEQ ID NO 1 , wherein said polynucleotide sequence may be identical to the reference sequence of SEQ ID NO 1 or may include up to a certain mteger number of nucleotide alterations as compared to the reference sequence, wherein said alterations are selected from the group consistmg of at least one nucleotide deletion, substitution, including transition and transversion, or insertion, and wherem said alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence, and wherein said number of nucleotide alterations is determined by multiplying the total number of nucleotides in SEQ ID NO 1 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of nucleotides m SEQ ID NO 1, or n n < x n " ( x n # y)> wherein n n is the number of nucleotide alterations, x n is the total number of nucleotides m SEQ ID NO 1, y is 0 95 for 95%. 0 97 for 97%, 0 99 for 99%, 0 995 for 99 5% or 1 00 for 100%, and • is the symbol for the multiplication operator, and wherein any non-mteger product of x n and y is rounded down to the nearest integer prior to subtracting it from x n Alterations of a polynucleotide sequence encoding the polypeptide of SEQ ID NO 2 may create nonsense, missense or frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the polynucleotide following such alterations (2) Polypeptide embodiments further include an isolated polypeptide comprising a polypeptide having at least a 95, 97 or 100% identity to a polypeptide reference sequence of SEQ ID NO 2, wherein said polypeptide sequence may be identical to the reference sequence of SEQ ID NO 2 or may include up to a certain integer number of ammo acid alterations as compared to the reference sequence, wherein said alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the ammo- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the ammo acids m the reference sequence or in one or more contiguous groups withm the reference sequence, and wherein said number of amino acid alterations is determined by multiplying the total number of ammo acids m SEQ ID NO 2 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of amino acids in SEQ ID NO 2, or n a < x a " ( x a * )> wherein n a is the number of amino acid alterations, x a is the total number of ammo acids in SEQ ID NO 2, y is 0 95 for 95%, 0 97 for 97% or 1 00 for 100%, and • is the symbol for the multiplication operator, and wherein any non-integer product of x a and y is rounded down to the nearest integer prior to subtracting it from x a "Indιvιdual(s)" means a multicellular eukaryote. including, but not limited to a metazoan. a mammal, an ovid. a bovid. a simian, a primate, and a human "Isolated" means altered "by the hand of man" from its natural state, / e . if it occurs m nature, it has been changed or removed from its ongmal environment, or both For example, a polynucleotide or a polypeptide naturalh. present m a living organism is not '"isolated," but the same polynucleotide or polypeptide separated from the coexisting matenals of its natural state is "isolated", as the term is employed herem Moreover, a polynucleotide or polypeptide that is mtroduced mto an organism by transformation, genetic manipulation or by any other recombinant method is "isolated" even if it is still present m said organism. which organism may be living or non-living "Organιsm(s)" means a (I) prokaryote, including but not limited to, a member of the genus Streptococcus, Staphylococcus, Bordetella, Corynebactenum, Mycobactenum, Neissena, Haemophύus, Actinomycetes, Streptomycetes, Nocardia, Enterobacter, Yersima, Fancisella Pasturella, Moraxella, Acinetobacter, Erysipelothnx, Branhamella, Actinobacillus, Streptobacillus, Listeria, Calymmatobactenum, Brucella, Bacillus, Clostndium, Treponema, Eschenchia, Salmonella, Kleibsiella, Vibrio, Proteus, Erwinia, Borreha, Leptospira, Spirillum, Campylobacter, Shigella, Legionella, Pseudomonas, Aeromonas, Rickettsia, Chlamydia, Borreha and Mycoplasma, and further including, but not limited to, a member of the species or group Group A Streptococcus, Group B Streptococcus, Group C Streptococcus, Group D Streptococcus, Group G Streptococcus, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus faecahs, Streptococcus faec um, Streptococcus durans, Neissena gonorrheae, Neissena meningit dis, Staphylococcus aureus, Staphylococcus epidermidis, Corynebactenum dipthenae, Gardnerella vagina s, Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium ulcerans, Mycobacterium leprae, Actinomyctes israelii, Listeria monocytogenes, Bordetella pertusis, Bordatella parapertusis, Bordetella bronchiseptica, Eschenchia coh, Shigella dysentenae, Haemophilus influenzae, Haemophilus aegyptius, Haemophύus parainfluenzae, Haemophilus ducreyi, Bordetella, Salmonella typhi, Citrobacter freundn, Proteus mirabihs, Proteus vulgar s, Yersinia pestis, Kleibsiella pneumoniae, Serratia marcessens, Serratia hquefaciens Vibrio cholera, Shigella dysenteru, Shigella flexnen, Pseudomonas aeruginosa, Franscisella tularensis, Brucella abortis, Bacillus anthracis, Bacillus cereus, Clostndium perfnngens, Clostndium tetani, Clostndium botuhnum, Treponema palhdum, Rickettsia nckettsn and Chlamydia trachomitis, (n) an archaeon, including but not limited to Archaebacter, and (in) a unicellular or filamentous eukaryote. including but not limited to, a protozoan, a fungus, a member of the genus Saccharomyces, Kluveromyces, or Candida, and a member of the species Saccharomyces cenviseae, Kluveromyces lactis, or Candida albicans "Polynucleotide(s)" generally refers to any polynbonucleotide or polydeoxyπbonucleotide, that may be unmodified RNA or DNA or modified RNA or DNA "Polynucleotide(s)" mclude, without limitation, smgle- and double-stranded DNA, DNA that is a mixture of smgle- and double-stranded regions or smgle-, double- and tnple-stranded regions, smgle- and double-stranded RNA. and RNA that is mixture of smgle- and double-stranded regions, hybπd molecules compπsmg DNA and RNA that may be smgle-stranded or, more typically, double-stranded, or tnple-stranded regions, or a mixture of smgle- and double-stranded regions In addition, "polynucleotide" as used herem refers to tnple-stranded regions compnsmg RNA or DNA or both RNA and DNA The strands m such regions may be from the same molecule or from different molecules The regions may mclude all of one or more of the molecules, but more typically mvolve only a region of some of the molecules One of the molecules of a tπple-hehcal region often is an oligonucleotide As used herem the teπn "polynucleotide(s)" also mcludes DNAs or RNAs as descnbed above that compπse one or more modified bases Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotide(s)" as that term is intended herem Moreover, DNAs or RNAs compπsmg unusual bases, such as mosme, or modified bases, such as tπtylated bases, to name just two examples, are polynucleotides as the term is used herem It will be appreciated that a great vanety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill m the art The term "polynucleotide(s)" as it is employed herem embraces such chemically, enzymatically or metabohcally modified forms of polynucleotides, as well as the chemical forms of DNA and RNA charactenstic of viruses and cells, including, for example, simple and complex cells "Polynucleotide(s)" also embraces short polynucleotides often refeπed to as ohgonucleotιde(s) "Polypeptide(s)" refers to any peptide or protem compπsmg two or more ammo acids jomed to each other by peptide bonds or modified peptide bonds "Polypeptide(s)" refers to both short chains, commonly refened to as peptides, oligopeptides and ohgomers and to longer chams generally refeπed to as proteins Polypeptides may compπse ammo acids other than the 20 gene encoded ammo acids "Polypeptide(s)" mclude those modified either by natural processes, such as processmg and other post-translational modifications, but also by chemical modification techmques Such modifications are well descπbed m basic texts and m more detailed monographs, as well as m a voluminous research literature, and they are well known to those of skill m the art It will be appreciated that the same type of modification may be present in the same or varying degree at several sites m a given polypeptide Also, a given polypeptide may compnse many types of modifications Modifications can occur anywhere m a polypeptide, including the peptide backbone, the ammo acid side-chains, and the ammo or carboxyl termini Modifications mclude, for example, acetylation, acylation, ADP-πbosylation. amidation. covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide deπvative, covalent attachment of a lipid or lipid deπvative, covalent attachment of phosphotidyhnositol, cross-linking, cyc zation. disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, GPI anchor formation, hydroxylation, lodination, methylation, mynstoylation, oxidation, proteolytic processmg, phosphorylation, prenylation, racemization, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-nbosylation. selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins, such as arginylation. and ubiquitination See. for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed . T E Creighton, W H Freeman and Company, New York (1993) and Wold, F , Posttranslational Protem Modifications Perspectives and Prospects, pgs 1-12 m POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B C Johnson, Ed , Academic Press. New York (1983), Seifter et al . Meth Enzymol 182 626-646 (1990) and Rattan et al . Protein Synthesis Posttranslational Modifications and Aging, Aim. Y Acad Sci 663 48-62 (1992) Polypeptides may be branched or cyclic, with or without branching Cyclic, branched and branched circular polypeptides may result from post- translational natural processes and may be made by entirely synthetic methods, as well "Recombinant expression system(s)" refers to expression systems or portions thereof or polynucleotides of the mvention mtroduced or transformed mto a host cell or host cell lysate for the production of the polynucleotides and polypeptides of the mvention 'Naπant(s)" as the term is used herein, is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties A typical variant of a polynucleotide differs nucleotide sequence from another, reference polynucleotide Changes in the nucleotide sequence of the variant may or may not alter the ammo acid sequence of a polypeptide encoded by the reference polynucleotide Nucleotide changes may result in ammo acid substitutions, additions, deletions, fusion proteins and truncations in the polypeptide encoded by the reference sequence, as discussed below A typical variant of a polypeptide differs in amino acid sequence from another, reference pohpeptide Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical A variant and reference polypeptide may differ in ammo acid sequence by one or more substitutions, additions, deletions in any combmation A substituted or inserted ammo acid residue may or may not be one encoded by the genetic code The present mvention also mcludes mclude vanants of each of the polypeptides of the mvention, that is polypeptides that vary from the referents by conservative ammo acid substitutions, whereby a residue is substituted by another with like characteπstics Typical such substitutions are among Ala, Val. Leu and He, among Ser and Thr, among the acidic residues Asp and Glu, among Asn and Gin, and among the basic residues Lys and Arg, or aromatic residues Phe and Tyr Particularly prefeπed are vaπants in which several, 5-10, 1-5, 1-3, 1-2 or 1 ammo acids are substituted, deleted, or added m any combmation A vanant of a polynucleotide or polypeptide may be a naturally occurring such as an allehc variant, or it may be a variant that is not known to occur naturally Non-naturally occurπng variants of polynucleotides and polypeptides may be made by mutagenesis techniques, by direct synthesis, and by other recombinant methods known to skilled artisans EXAMPLES The examples below are earned out usmg standard techmques, that are well known and routme to those of skill m the art. except where otherwise descnbed m detail The examples are illustrative, but do not limit the mvention Example 1 Strain selection, Library Production and Sequencing The polynucleotide having a DNA sequence given m Table 1 [SEQ ID NO 1] was obtained from a library of clones of chromosomal DNA of Streptococcus pneumoniae in E cob The sequencmg data from two or more clones comprising overlapping Streptococcus pneumoniae DNAs was used to construct the contiguous DNA sequence in SEQ ID NO 1 Libraries may be prepared by routine methods, for example Methods 1 and 2 below Total cellular DNA is isolated from Streptococcus pneumoniae 0100993 according to standard procedures and size-fractionated by either of two methods Method 1 Total cellular DNA is mechanically sheared by passage through a needle m order to size- fractionate according to standard procedures DNA fragments of up to l lkbp m size are rendered blunt by treatment with exonuclease and DNA polymerase. and EcoRI linkers added Fragments are ligated into the vector Lambda ZapII that has been cut with EcoRI, the library packaged by standard procedures and E coli infected with the packaged library The library is amplified by standard procedures Method 2 Total cellular DNA is partially hydrolyzed with a one or a combination of restriction enzymes appropriate to generate a series of fragments for cloning mto library vectors (e g , Rsal, Pall, Alul, Bshl235I), and such fragments are size-fractionated according to standard procedures EcoRI linkers are ligated to the DNA and the fragments then ligated mto the vector Lambda ZapII that have been cut with EcoRI, the library packaged by standard procedures, and E cob infected with the packaged library The library is amplified by standard procedures Example 2 murF2 Characterization The S. pneumoniae murF2 gene is expressed during infection in a respiratory tract infection model The determination of expression during infection of a gene from Streptococcus pneumoniae Excised lungs from a 48 hour respiratory tract infection of Streptococcus pneumoniae 0100993 m the mouse is efficiently disrupted and processed in the presence of chaotropic agents and RNAase inhibitor to provide a mixture of anunal and bacterial RNA The optimal conditions for disruption and processing to give stable preparations and high yields of bacterial RNA are followed by the use of hybridisation to a radiolabelled oligonucleotide specific to Streptococcus pneumoniae 16S RNA on Northern blots The RNAase free, DNAase free, DNA and protem free preparations of RNA obtamed are suitable for Reverse Transcription PCR (RT-PCR) usmg unique pnmer pairs designed from the sequence of each gene of Streptococcus pneumoniae 0100993 a) Isolation of tissue infected with Streptococcus pneumoniae 0100993 from a mouse animal model of infection (lungs) Streptococcus pneumoniae 0100993 is seeded onto TSA (Tryptic Soy Agar, BBL) plates containing 5% horse blood and allowed to grow overnight at 37°C in a C02 incubator Bacterial growth is scraped mto 5 ml of phosphate-buffered salme (PBS) and adjusted to an A600 ~ 0 6 (4 x 106/ml) Mice (male CBA/J-1 mice, approximately 20g) were anaesthetized with lsoflurane and 50 microhters of the prepared bacterial inoculum is delivered by mtranasal instillation Animals are allowed to recover and observed twice daily for signs of monbundancy Forty-eight hours after infection the animals are euthanized by carbon dioxide overdose and their torsos swabbed with ethanol and then RNAZap The torso is then opened, and the lungs are aseptically removed Half of each pair of lungs is placed in a cryovial and immediately frozen in liquid nitrogen, the other half is used for bacterial enumeration after homogemzation of the tissue m 1 ml of PBS b) Isolation of Streptococcus pneumoniae 0100993 RNA from infected tissue samples Infected tissue samples, in 2-ml ciy o-strorage tubes, are removed from -80°C storage mto a dry ice ethanol bath In a microbiological safety cabinet the samples are disrupted up to eight at a time while the remaining samples are kept frozen m the dry ice ethanol bath To disrupt the bacteria withm the tissue sample, 50-100 mg of the tissue is transfered to a FastRNA tube containing a silica/ceramic matrix (BIO 101) Immediately, 1 ml of extraction reagents (FastRNA reagents, BIOIOI) are added to give a sample to reagent volume ratio of approximately 1 to 20 The tubes are shaken in a reciprocating shaker (FastPrep FP120, BIOIOI) at 6000 rpm for 20-120 sec The crude RNA preparation is extracted with chloroform/isoamyl alcohol, and precipitated with DEPC-treated/Isopropanol Precipitation Solution (BIOIOI) RNA preparations are stored in this isopropanol solution at -80°C if necessary The RNA is pelleted (12,000g for 10 mm ), washed with 75% ethanol (v/v in DEPC-treated water), air-dried for 5-10 mm, and resuspended in 0 1 ml of DEPC-treated water, followed by 5-10 minutes at 55 oC Finally, after at least 1 minute on ice, 200 units of Rnasm (Promega) is added RNA preparations are stored at -80 oC for up to one month For longer term storage the RNA precipitate can be stored at the wash stage of the protocol in 75% ethanol for at least one year at -20 oC Quality of the RNA isolated is assessed by running samples on 1% agarose gels 1 x TBE gels stained with ethidium bromide are used to visualise total RNA yields To demonstrate the isolation of bacterial RNA from the infected tissue 1 x MOPS. 2 2M formaldehyde gels are run and vacuum blotted to Hybond-N (Amersham) The blot is then hybridised with a 32P-labelled ohgonucletide probe, of sequence 5' AACTGAGACTGGCTTTAAGAGATTA 3' [SEQ ID NO 3], specific to 16S rRNA of Streptococcus pneumoniae The size of the hybridising band is compared to that of control RNA isolated from m vitro grown Streptococcus pneumoniae 0100993 m the Northern blot Correct sized bacterial 16S rRNA bands can be detected in total RNA samples which show degradation of the mammalian RNA when visualised on TBE gels c) The removal of DNA from Streptococcus pneumoniae-deπved RNA DNA was removed from 50 microgram samples of RNA by a 30 mmute treatment at 37°C with 20 units of RNAase-free DNAasel (GenHunter) in the buffer supplied m a final volume of 57 microhters The DNAase was inactivated and removed by treatment with TRIzol LS Reagent (Gibco BRL, Life Technologies) according to the manufacturers protocol DNAase treated RNA was resuspended m 100 microhtres of DEPC treated water with the addition of Rnasin as described before d) The preparation of cDNA from RNA samples derived from infected tissue 3 microgram samples of DNAase treated RNA are reverse transcribed using a Superscript Preamphfication System for First Strand cDNA Synthesis kit (Gibco BRL, Life Technologies) accordmg to the manufacturers instructions 150 nanogram of random hexamers is used to prime each reaction Controls without the addition of SuperScπptll reverse transcπptase are also run Both +/-RT samples are treated with RNaseH before proceeding to the PCR reaction e) The use of PCR to determine the presence of a bactenal cDNA species PCR reactions are set up on ice in 0 2ml tubes by adding the following components 43 microhtres PCR Master Mix (Advanced Biotechnologies Ltd ), 1 microhtre PCR primers (optimally 18- 25 basepairs in length and designed to possess similar annealing temperatures), each primer at lOmM initial concentration, and 5 microhtres cDNA PCR reactions are run on a Perkm Elmer GeneAmp PCR System 9600 as follows 2 minutes at 94 oC, then 50 cycles of 30 seconds each at 94 oC, 50 oC and 72 oC followed by 7 minutes at 72 oC and then a hold temperature of 20 oC (the number of cycles is optimally 30-50 to determine the appearance or lack of a PCR product and optimally 8-30 cycles if an estimation of the starting quantity of cDNA from the RT reaction is to be made), 10 microhtre aliquots are then run out on 1% 1 x TBE gels stained with ethidium bromide, ith PCR product, if present, sizes estimated by comparison to a 100 bp DNA Ladder (Gibco BRL. Life Technologies) Alternatively if the PCR products are conveniently labelled by the use of a labelled PCR primer (e g labelled at the 5'end with a dye) a suitable aliquot of the PCR product is run out on a polyacrylamide sequencing gel and its presence and quantity detected using a suitable gel scanning system (e g ABI PπsmTM 377 Sequencer using GeneScanTM software as supplied by Perkin Elmer) RT/PCR controls may include +/- reverse transcπptase reactions, 16S rRNA primers or DNA specific primer pairs designed to produce PCR products from non-transcπbed Streptococcus pneumoniae 0100993 genomic sequences To test the efficiency of the primer pairs they are used in DNA PCR with Streptococcus pneumoniae 0100993 total DNA PCR reactions are set up and run as described above using approx 1 microgram of DNA m place of the cDNA Primer pairs which fail to give the predicted sized product in either DNA PCR or RT/PCR are PCR failures and as such are uninformative Of those which give the correct size product with DNA PCR two classes are distinguished m RT/PCR 1 Genes which are not transcribed in vivo reproducibly fail to give a product in RT/PCR, and 2 Genes which are transcribed m vivo reproducibly give the correct size product in RT/PCR and show a stronger signal m the +RT samples than the signal (if at all present) m -RT controls Example 3 The murF2 gene is essential for S. pneumoniae in vitro growth. Demonstration of gene essentiality to bacterial viability An allehc replacement cassette was generated usmg PCR technology The cassette consisted of a pair of 500bp chromosomal DNA fragments flanking an erythromycin resistance gene The chromosomal DNA sequences are the 500bp preceding and following the DNA sequence encoding the murF2 gene contained in Seq ID NO 1 The allehc replacement cassette was introduced mto S pneumoniae R6 by transformation Competent cells were prepared according to published protocols DNA was introduced mto the cells by incubation of ng quantities of allehc replacement cassette with 10" cells at 30°C for 30 minutes The cells were transferred to 37°C for 90 mmutes to allow expression of the erythromycin resistance gene Cells were plated in agar containing lug erythromycin per ml Following incubation at 37°C for 36 hours, colonies are picked and grown overnight Todd-Hewitt broth supplemented with 0 5% yeast extract Typically 1000 transformants containing the appropriate allehc replacement are obtained If no transformants are obtained m three separate transformation experiments as was the case for this gene murF2. then the gene is considered as being essential in vitro

Claims: What is claimed is: 1 An isolated polypeptide selected from the group consisting of (1) an isolated polypeptide comprising an amino acid having at least 95% identity to the ammo acid sequence of SEQ ID NO 2 over the entire length of SEQ ID NO 2, (n) an isolated polypeptide comprising the ammo acid sequence of SEQ ID NO 2, (in) an isolated polypeptide that is the amino acid sequence of SEQ ID NO 2, and (IV) a polypeptide that is encoded by a recombinant polynucleotide comprising the polyncleotide sequence of SEQ ID NO 1 2 An isolated polynucleotide selected from the group consisting of (I) an isolated polynucleotide compnsmg a polynucleotide sequence encoding a polypeptide that has at least 95 % identity to the ammo acid sequence of SEQ ID NO 2, over the entire length of SEQ ID NO 2, (n) an isolated polynucleotide compnsmg a polynucleotide sequence that has at least 95% identity over its entire length to a polynucleotide sequence encoding the polypeptide of SEQ ID NO 2, (m) an isolated polynucleotide compnsmg a nucleotide sequence that has at least 95% identity to that of SEQ ID NO 1 over the entire length of SEQ ID NO 1, (iv) an isolated polynucleotide compnsmg a nucleotide sequence encoding the polypeptide of SEQ ID NO 2, (v) an isolated polynucleotide that is the polynucleotide of SEQ ID NO 1 , (vi) an isolated polynucleotide of at least 30 nucleotides m length obtainable by screenmg an appropnate library under strmgent hybπdization conditions with a probe havmg the sequence of SEQ ID NO 1 or a fragment thereof of of at least 30 nucleotides m length, (vu) an isolated polynucleotide encoding a mature polypeptide expressed by the murF2 gene compnsed in the Streptococcus pneumoniae, and (viu) a polynucleotide sequence complementary to said isolated polynucleotide of (I), (n), (m), (iv), (v), (vi) or (vn) 3 A method for the treatment of an individual (I) in need of enhanced activity or expression of or lmmunological response to the polypeptide of claim 1 comprising the step of administering to the individual a therapeutically effective amount of an antagonist to said polypeptide, or (n) having need to inhibit activity or expression of the polypeptide of claim 1 comprising (a) administering to the mdividual a therapeutically effective amount of an antagonist to said polypeptide, or (b) administering to the mdividual a nucleic acid molecule that inhibits the expression of a polynucleotide sequence encoding said polypeptide, (c) administering to the individual a therapeutically effective amount of a polypeptide that competes with said polypeptide for its ligand, substrate, or receptor, or (d) administering to the mdividual an amount of a polypeptide that mduces an lmmunological response to said polypeptide m said individual 4 A process for diagnosing or prognosing a disease or a susceptibility to a disease m an individual related to expression or activity of the polypeptide of claim 1 m an mdividual comprising the step of (a) determining the presence or absence of a mutation m the nucleotide sequence encoding said polypeptide in an organism in said individual, or (b) analyzing for the presence or amount of said polypeptide expression in a sample denved from said individual 5 A process for producing a polypeptide selected from the group consisting of (l) an isolated polypeptide compnsmg an amino acid sequence selected from the group having at least 95% identity to the amino acid sequence of SEQ ID NO 2 over the entire length of SEQ ID NO 2, (n) an isolated polypeptide compπsmg the amino acid sequence of SEQ ID NO 2, (in) an isolated polypeptide that is the amino acid sequence of SEQ ID NO 2, and (iv) a polypeptide that is encoded by a recombinant polynucleotide compπsmg the polynucleotide sequence of SEQ ID NO 1, comprising the step of cultuπng a host cell under conditions sufficient for the production of the polypeptide 6 A process for producing a host cell comprising an expression system or a membrane thereof expressing a polypeptide selected from the group consisting of (I) an isolated polypeptide compnsmg an ammo acid sequence selected from the group having at least 95% identity to the ammo acid sequence of SEQ ID NO 2 over the entire length of SEQ ID NO 2, (ii) an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2; (iii) an isolated polypeptide that is the amino acid sequence of SEQ ID NO:2, and (iv) a polypeptide that is encoded by a recombinant polynucleotide comprising the polynucleotide sequence of SEQ ID NO:l, said process comprising the step of transforming or transfecting a cell with an expression system comprising a polynucleotide capable of producing said polypeptide of (i), (ii), (iii) or (iv) when said expression system is present in a compatible host cell such the host cell, under appropriate culture conditions, produces said polypeptide of (i), (ii), (iii) or (iv). 7. A host cell or a membrane expressing a polypeptide selected from the group consisting of: (i) an isolated polypeptide comprising an amino acid sequence selected from the group having at least 95% identity to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2; (ii) an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2; (iii) an isolated polypeptide that is the amino acid sequence of SEQ ID NO:2, and (iv) a polypeptide that is encoded by a recombinant polynucleotide comprising the polynucleotide sequence of SEQ ID NO:l. 8. An antibody immunospecific for the polypeptide of claim 1. 9. A method for screening to identify compounds that agonize or that inhibit the function of the polypeptide of claim 1 that comprises a method selected from the group consisting of: (a) measuring the binding of a candidate compound to the polypeptide (or to the cells or membranes bearing the polypeptide) or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound; (b) measuring the binding of a candidate compound to the polypeptide (or to the cells or membranes bearing the polypeptide) or a fusion protein thereof in the presence of a labeled competitor; (c) testing whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells or cell membranes bearing the polypeptide; (d) mixing a candidate compound with a solution comprising a polypeptide of claim 1, to form a mixture, measuring activity of the polypeptide in the mixture, and comparing the activity of the mixture to a standard; or (e) detecting the effect of a candidate compound on the production of mRNA encoding said polypeptide and said polypeptide in cells, using for instance, an ELISA assay. 10. An agonist or antagonist to the polypeptide of claim 1.

Inventors: BISWAS SANJOY, BROWN JAMES R, BURNHAM MARTIN K R, CHALKER ALISON F, HOLMES DAVID J, INGRAHAM KAREN A, MATHIE THOMAS B, WARREN RICHARD L, ZALACAIN MAGDALENA, BISWAS, SANJOY, BROWN, JAMES, R., BURNHAM, MARTIN, K., R., CHALKER, ALISON, F., HOLMES, DAVID, J., INGRAHAM, KAREN, A., MATHIE, THOMAS, B., WARREN, RICHARD, L., ZALACAIN, MAGDALENA
Applicants: SMITHKLINE BEECHAM CORP, SMITHKLINE BEECHAM CORPORATION
Application year: 1999
Main classification: A01N63
IPC codes: A61K31, A61K38, A61K45, A61K48, A61P31, A61P35, C07K14, C07K16, C12N1, C12N5, C12N15, C12P21, C12Q1, C12R1, G01N33